Dissemin is shutting down on January 1st, 2025

Published in

Nature Research, Nature Cancer, 2(3), p. 251-261, 2022

DOI: 10.1038/s43018-022-00332-x

Links

Tools

Export citation

Search in Google Scholar

The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology

Journal article published in 2022 by David Tamborero, Maan Haj Rachid, Jeffrey Yachnin, Rodrigo Dienstmann, Richard D. Baird, Jorrit Boekel, Xenia Villalobos, Adria Lopez-Fernandez, Christophe Massard, Patricia Martin-Romano, Markus Jonsson, Frans Opdam, Ali Razzak, Richard F. Schlenk, Shubha Anand and other authors.
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Orange circle
Postprint: archiving restricted
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

AbstractThere is a growing need for systems that efficiently support the work of medical teams at the precision-oncology point of care. Here, we present the implementation of the Molecular Tumor Board Portal (MTBP), an academic clinical decision support system developed under the umbrella of Cancer Core Europe that creates a unified legal, scientific and technological platform to share and harness next-generation sequencing data. Automating the interpretation and reporting of sequencing results decrease the need for time-consuming manual procedures that are prone to errors. The adoption of an expert-agreed process to systematically link tumor molecular profiles with clinical actions promotes consistent decision-making and structured data capture across the connected centers. The use of information-rich patient reports with interactive content facilitates collaborative discussion of complex cases during virtual molecular tumor board meetings. Overall, streamlined digital systems like the MTBP are crucial to better address the challenges brought by precision oncology and accelerate the use of emerging biomarkers.